The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC Sept 2021 | Amivantamab for NSCLC with MET Exon 14 skipping mutations
Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, Fairfax, VA, discusses the use of amivantamab, a bispecific antibody targeting EGFR and MET, which was initially investigated to overcome EGFR mechanisms of resistance. He describes the ongoing Phase I CHRYSALIS study (NCT02609776) of amivantamab in patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutations. Initial data obtain has demonstrated clinical benefit, including in patients previously treated with tyrosine kinase inhibitors (TKIs), however, Dr Spira highlights the importance of determining the role of amivantamab in the treatment paradigm and whether it can replace TKIs in the future. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
